BUDESINID NOVOLIZER® EFFICACY AND SAFETY IN CONTROLLER THERAPY PATIENTS WITH PERSISTENT BRONCHIAL ASTHMA STUDY RESULTS

Y. I. Feshchenko, L. A. Yashyna, M. A. Polianska, I. V. Zvol, S. G. Ishchuk, I. V. Chumak, L. A. Savelieva, R. M. Zagrebelniy

Summary. The budesonid Novolizer® efficacy and safety as controller therapy in patients with persistent bronchial asthma was investigated. Use of high effective inhaled corticosteroid budesonid in effective device Novolizer® leads to the improvement of asthma contril — reduce asthma symptoms, decrease bronchial hyperresponsiveness, improve of patient's therapy adherence.

Key words: bronchial asthma, anti-inflammation therapy, budesonid, Tafen, Novolizer $^{\otimes}$, novopulmon.